Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel announced it's submitted a NDA to the FDA for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12+.
Read the full article15y agoen
You might also wanna read
OpenAI No. 2 Executive Fidji Simo Steps Down from Full-Time Role to Focus on Health Recovery
Variety·4h ago
Why ambulance rides in the US are so expensive: The broken economics of emergency medical transport
davidoks.blog·6h agoModerna's mResvia gets shot in the arm from EU contract
pharmaphorum·6h ago
Australia news live: Hanson defends UK ‘fact-finding’ trip; Qantas tops airline punctuality table
The Guardian·6h ago
STAT+: FDA finalists under review
STAT·13h ago
STAT+: Prime wins Beam arbitration, clearing path to clinic
STAT·14h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.